Events

October 26 -29, Singapore

October 26 -29, Singapore

American Society of Hematolgy (ASH) 2021 guideline recommendation for venous thromboembolism management in cancer patients, they are suggest using thromboprophylaxis in cancer patients admit in hospital over no prophylaxis, suggest using LMWH over UFH and suggest discontinuation of thromboprophylaxis at a time of discharge. In addition summary of biosimilarity for biological product,  biologics product are different and more complex than chemicals product. Biosimilar registration dossier is composed of a full set of data (quality, non-clinical & clinical data),  and based on head to head comparison with the reference product. Europe and US Health Authorities (EMA & FDA) have developed specific guidelines for LMWH and enoxaparin. LMWH immunogenicity can be influenced by the manufacturing process (e.g. impurities). It is important to closely monitor clinical safety of these products through adequate pharmacovigilance system.

Epilepsy is a heterogeneous condition requiring treatments be individualized, mainly based upon patient’s seizure syndrome and seizure type. In this, Anti-epileptic drugs (AEDs) represent a mainstay of treatment. Despite with more than 10 different AEDs be available for tailoring to aggressiveness, at least one-third of patients remain suffering from spontaneous and recurrent seizures.

Despite adequacies in AED treatments and adherence, and the emergence of newer AEDs, over 30% of patients with epilepsy remain refractory to treatment and are said to have drug-resistant epilepsy (DRE). DRE is a serious problem that can be associated with developmental delay in infants & young children, and severe disability and morbidity in older children & adults, as well as a mortality rate 5-10 times higher than the general population, due primarily to sudden unexpected death in epilepsy, accidents, suicide.

We all agree that when discussing the treatment of epilepsy, targeted populations need to be defined. Three patient groups, children, the elderly, and women, are considered “special” because of metabolic and physical differences that require particular care during treatment of this disease. Treatment options vary significantly among these populations.